company background image
BDRX logo

Biodexa Pharmaceuticals AIM:BDRX Stock Report

Last Price

UK£0.037

Market Cap

UK£3.5m

7D

-16.7%

1Y

-98.5%

Updated

27 Apr, 2023

Data

Company Financials

Biodexa Pharmaceuticals Plc

AIM:BDRX Stock Report

Market Cap: UK£3.5m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

BDRX Stock Overview

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing products aimed at primary and metastatic cancers of the brain in the United Kingdom.

BDRX fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Biodexa Pharmaceuticals Plc Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Biodexa Pharmaceuticals
Historical stock prices
Current Share PriceUK£0.037
52 Week HighUK£3.18
52 Week LowUK£0.038
Beta1.13
1 Month Change-76.56%
3 Month Change-90.38%
1 Year Change-98.47%
3 Year Change-99.59%
5 Year Change-99.97%
Change since IPO-100.00%

Recent News & Updates

Recent updates

Here's Why Midatech Pharma (LON:MTPH) Must Use Its Cash Wisely

May 17
Here's Why Midatech Pharma (LON:MTPH) Must Use Its Cash Wisely

Midatech Pharma plc (LON:MTPH) Insiders Have Been Selling

Feb 24
Midatech Pharma plc (LON:MTPH) Insiders Have Been Selling

Shareholder Returns

BDRXGB BiotechsGB Market
7D-16.7%1.7%2.2%
1Y-98.5%-27.5%3.7%

Return vs Industry: BDRX underperformed the UK Biotechs industry which returned -15.3% over the past year.

Return vs Market: BDRX underperformed the UK Market which returned -1% over the past year.

Price Volatility

Is BDRX's price volatile compared to industry and market?
BDRX volatility
BDRX Average Weekly Movement19.9%
Biotechs Industry Average Movement7.9%
Market Average Movement4.8%
10% most volatile stocks in GB Market11.3%
10% least volatile stocks in GB Market2.6%

Stable Share Price: BDRX's share price has been volatile over the past 3 months.

Volatility Over Time: BDRX's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of UK stocks.

About the Company

FoundedEmployeesCEOWebsite
200020Stephen Stamphttps://www.biodexapharma.com

Biodexa Pharmaceuticals Plc, a drug delivery technology company, focuses on the bio-delivery and biodistribution of medicines in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and MTD219, a long-acting formulation of tacrolimus used to lower the risk of organ transplant rejection. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents.

Biodexa Pharmaceuticals Plc Fundamentals Summary

How do Biodexa Pharmaceuticals's earnings and revenue compare to its market cap?
BDRX fundamental statistics
Market capUK£3.55m
Earnings (TTM)-UK£5.37m
Revenue (TTM)UK£645.00k

5.5x

P/S Ratio

-0.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BDRX income statement (TTM)
RevenueUK£645.00k
Cost of RevenueUK£4.65m
Gross Profit-UK£4.01m
Other ExpensesUK£1.36m
Earnings-UK£5.37m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.057
Gross Margin-621.55%
Net Profit Margin-832.09%
Debt/Equity Ratio0%

How did BDRX perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.